NMPA Announces Digitalization of Medical Device Regulatory Documents
The National Medical Products Administration (NMPA) has announced a transition to digitalize regulatory documentation for...
Policy / Regulatory
China’s NHSA Launches New Procedures for Drug Catalogue Attribution Identification
The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and...
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate...
China’s CDE Issues Draft Guidelines for Patient-Centric Rare Disease Drug R&D
The Center for Drug Evaluation (CDE) has issued a notification regarding the patient-centric rare disease...
China’s NHSA Aims to Boost Medical Insurance Reform with Sanming Model
The National Healthcare Security Administration (NHSA) has issued a notification aimed at promoting the medical...
NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...
Guangzhou Boosts Innovative Drug Development with New HSA Initiatives
The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...
China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...
FDA Alert: Chinese Syringe Maker Jiangsu Shenli Initiates Voluntary Recall
This week, the US Food and Drug Administration (FDA) provided a status report on its...
China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023
The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...
NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels
The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...
China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation
The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...
China’s Health Commission Boosts Efforts to Monitor and Respond to Drug Shortages
The National Health Commission (NHC) of China has recently announced the reinforcement of national and...
Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment
The US House Committee on Oversight and Accountability has completed the markup process for amendments...
US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports
The US Office of the Trade Representative (USTR) has announced a series of stringent new...
China Launches Nationwide Unannounced Inspections of Medical Insurance Funds
An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
NMPA Updates In Vitro Diagnostic Reagents Classification List for Enhanced Regulatory Oversigh
The National Medical Products Administration (NMPA) has coordinated the revision and release of the In...
China’s NMPA Revamps Medical Device Classification Rules to Improve Regulatory Efficiency
The National Medical Products Administration (NMPA) has revised the “Notice on Standardizing the Classification of...